B+
Bull case
25%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
CADL
Candel TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$14.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-07
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Company-led newsflow is constructive, centered on the positive phase 3 prostate result, Q4 2026 BLA plan, AURORA activation, commercial hiring, and stated runway [#PR-EARNINGS-2026-08-13]. Social, options, short-interest, employee-review, and analyst-revision data are unavailable or insufficient in the packet. This supports a monitoring-oriented speculative setup rather than a high-confidence re-rating thesis.
RankAlpha Sentiment Codex - 2026-09-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventASTRO biomarker data may strengthen the prostate-cancer filing caseHigh impact
Candel expects to present extended biomarker data from its phase 3 localized-prostate-cancer trial at the ASTRO Annual Meeting in Q3 2026. Detailed results are not yet available, so the signal remains event-driven and uncertain [#SEC-8K-2026-08-13].
2026-12-31eventPlanned Q4 2026 BLA submission for aglatimageneHigh impact
Candel plans to submit a BLA for aglatimagene in localized, intermediate- to high-risk prostate cancer during Q4 2026. The company cites statistically significant disease-free-survival improvement in pivotal phase 3 data, but submission timing and regulatory outcome remain execution-sensitive [#SEC-8K-2026-08-13].
2027-12-31catalystPotential 2027 commercial launch if approvedHigh impact
Candel is building commercial readiness for a potential 2027 U.S. launch, including the appointment of a chief commercial officer, while stating that cash is expected to fund the current operating plan into Q1 2028. This upside remains contingent on BLA acceptance, approval, manufacturing, and launch execution [#PR-EARNINGS-2026-08-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-07 • Updated nightlySource: Internal modelMethodology